The first patient use was for an ankle surgery. The debut marks Ossium Health’s entrance into the orthobiologics market.
“We’ve always strived to maximize the positive impact of each organ donor’s generous gift,” Kevin Caldwell, the company’s president, CEO and co-founder, said in the release. “First, we developed a life-saving product from organ donor bone marrow, which didn’t previously have an established therapeutic application. With the development of OssiGraft, we’re expanding the impact of each donor’s gift even further.”
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
